|Articles|June 14, 2004

FDA clears handheld ultrasound

A new lightweight handheld ultrasound unit may soon be on the U.S. market. The FDA has cleared for sale the Mobilsonic VUE100, a low-cost device weighing less than three pounds. The system was developed by Mobilsonic and will be distributed in the U.S.

A new lightweight handheld ultrasound unit may soon be on the U.S. market. The FDA has cleared for sale the Mobilsonic VUE100, a low-cost device weighing less than three pounds. The system was developed by Mobilsonic and will be distributed in the U.S. by Bierley Ultrasound.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Subscribe Now!

Latest CME

Video

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

FDA clears handheld ultrasound

Newsletter

Related Content

Fujifilm Sonosite Unveils Next-Generation Point-of-Care Ultrasound Device

Can Ultrasound-Derived Fat Fraction Provide a Viable Alternative for Quantifying Hepatic Steatosis?

FDA Grants De Novo Approval for Home Use of Prenatal Ultrasound Platform

Ultrasound Renal Denervation System for Hypertension Garners CMS National Coverage Determination

FDA Clears Emerging Intracardiac Ultrasound System

Latest CME

26th Annual International Lung Cancer Congress

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

20th Annual New York Lung Cancers Symposium®

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

23rd Annual Winter Lung Cancer Conference®

43rd Annual Miami Breast Cancer Conference®

19th Annual New York GU Cancers Congress™

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

2026 International Symposium of Gastrointestinal Oncology (ISGIO)

26th Annual International Lung Cancer Congress

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on Diagnostic Imaging

Nine Takeaways from New Review of PSMA PET/CT and Whole-Body MRI for Advanced Prostate Cancer

Study Shows Merits of CT Vascular Sign for Differentiating Solid Pulmonary Nodules

A Closer Look at New Guidelines for Molecular Imaging of Renal Masses: An Interview with Steven Rowe, MD, Part 2